Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Ensartinib capsules in healthy volunteers
NCT05665283Phase 1Completed
- Sponsor
- Xcovery
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ensartinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Xcovery. Primary endpoints: Maximum Plasma Concentration at 14 days, Area Under the Curve to the Last Quantifiable Concentration at 14 days and 1 more. Started Nov 2022; status: completed.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05665283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665283.